| 275 Armand-Frappier Blvd. | Phone: +1-450-680-4500 |
| Laval, QC | Fax: +1-450-680-4501 |
| H7V 4A7 | |
| Canada | 
Map This Company |
Bellus Health Inc. Rankings
Company Description
Bellus Health scientists are putting their gray matter to work to find therapies for incurable conditions. Bellus Health's lead candidate is a potential treatment for Amyloid A amyloidosis, an often fatal condition associated with inflammatory disease and kidney dysfunction. Bellus has licensed the late-stage compound to Celtic Therapeutics for about $10 million. Celtic will market the drug under the name Kiacta. Bellus is also evaluating a potential treatment for type 2 diabetes in clinical trials and has discovery programs in the areas of Alzheimer's disease, diabetes, and metabolic syndrome.
Bellus Health Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - Toronto: BLU Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 22 |
Executives
15 executives listed for Bellus Health Inc.'s Laval, QC location.
| Chairman, President, and CEO | Francesco Bellini | |
|---|---|---|
| VP Finance and CFO | Mariano Rodriguez | |
| SVP Drug Development | Denis Garceau |